Evidence map›Paper›PMID 29099873›Full record

ArticlePloS one2017

Assessing Zika virus replication and the development of Zika-specific antibodies after a mid-gestation viral challenge in guinea pigs.

Craig J Bierle, Claudia Fernández-Alarcón, Nelmary Hernandez-Alvarado, Jason C Zabeli, Bradley C Janus, Dira S Putri, Mark R Schleiss

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Comparative Animal Models of Human Viral Infections.Pathogens (Basel, Switzerland) · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Craig J BierleDivision of Pediatric Infectious Disease and Immunology, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United States of America.ORCID http://orcid.org/0000-0002-7890-7409
Claudia Fernández-AlarcónDivision of Pediatric Infectious Disease and Immunology, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United States of America.
Nelmary Hernandez-AlvaradoDivision of Pediatric Infectious Disease and Immunology, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United States of America.
Jason C ZabeliDivision of Pediatric Infectious Disease and Immunology, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United States of America.
Bradley C JanusDivision of Pediatric Infectious Disease and Immunology, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United States of America.
Dira S PutriDivision of Pediatric Infectious Disease and Immunology, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United States of America.
Mark R SchleissDivision of Pediatric Infectious Disease and Immunology, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United States of America.
University of Minnesota · US

Funding

Minnesota Craniofacial Research Training ProgramT90DE022732 · NIDCR · UNIVERSITY OF MINNESOTA · PI MANSKY, KIM CARPENTER · 2012 to 2023
$4.9M
Viral Immunomodulation and Rational CMV Vaccine DesignR01HD044864 · NICHD · UNIVERSITY OF MINNESOTA TWIN CITIES · PI GEBALLE, ADAM P., MCVOY, MICHAEL A · 2003 to 2015
$4.5M
Minnesota Training Program in VirologyT32AI083196 · NIAID · UNIVERSITY OF MINNESOTA · PI Louis M Mansky · 2010 to 2026
$3.2M
Optimized Vaccines Against Congenital Infection and Maternal Reinfection with CMVR01HD079918 · NICHD · UNIVERSITY OF MINNESOTA · PI SCHLEISS, MARK R. · 2015 to 2019
$1.6M
Defining the viral determinants of cytomegalovirus transplacental transmissionR21HD087496 · NICHD · UNIVERSITY OF MINNESOTA · PI BIERLE, CRAIG JOHN · 2017 to 2018
$420k
Preclinical Evaluation of a Novel rLCMV Single-Cycle Vectored CMV VaccineR56AI114013 · NIAID · UNIVERSITY OF MINNESOTA · PI SCHLEISS, MARK R. · 2015 to 2015
$342k
ELISPOT Peptide Mapping Assay to Identify Novel Candidate CMV Vaccine AntigensR03HD082273 · NICHD · UNIVERSITY OF MINNESOTA · PI SCHLEISS, MARK R. · 2015 to 2016
$151k
NIAID NIH HHS R56 AI114013NIAID NIH HHS T32 AI083196NICHD NIH HHS R01 HD044864NICHD NIH HHS R01 HD079918NICHD NIH HHS R03 HD082273NICHD NIH HHS R21 HD087496NIDCR NIH HHS T90 DE022732
6 · The paper itself

Abstract

Primary Zika virus (ZIKV) infections that occur during pregnancy can cause spontaneous abortion and profoundly disrupt fetal development. While the full range of developmental abnormalities associated with congenital Zika syndrome is not yet known, severe cases of the syndrome can present with microcephaly, extensive neurologic and ocular damage, and pronounced joint malformations. Animal models that accurately recapitulate congenital Zika syndrome are urgently needed for vaccine development and for the study of ZIKV pathogenesis. As guinea pigs have successfully been used to model transplacental infections by cytomegalovirus, syphilis, and Listeria monocytogenes, we sought to test whether ZIKV could productively infect guinea pigs and whether viral transmission with attendant fetal pathology would occur after a mid-gestation viral challenge. We found that guinea pig cells supported ZIKV replication in vitro. Experimental infection of non-pregnant animals did not result in overt disease but low-level, detectable viremia was observed. When pregnant guinea pigs were challenged with ZIKV at between 18 and 21 days gestational age, ZIKV was not detected in maternal or pup blood, plasma, or tissues and no significant differences in maternal weight gain or pup size were observed following challenge. Nonetheless, a robust antibody response against ZIKV was detected in both the pups and dams. These results suggest that, while guinea pigs can model aspects of the immune response to ZIKV infection during pregnancy, naturally circulating ZIKV strains are not pathogenic during the pregnancy of immunocompetent guinea pigs and do not interfere with normal pup development.

Indexed as

Disease Models, AnimalVirus ReplicationAnimalsAntibodies, ViralFemaleGuinea PigsMaternal-Fetal ExchangePregnancyPregnancy Complications, InfectiousViremiaZika VirusZika Virus InfectionAntibodies, Viral

Identifiers

PMID29099873
PMCPMC5669436
OpenAlexW2765612811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.